{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:02:16Z","timestamp":1789650136807,"version":"4.0.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bneo.2026.100283","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:53:12Z","timestamp":1786445592000},"page":"100283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival benefit of chemoradiotherapy in limited-stage mantle cell lymphoma: a National Cancer Database analysis"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3253-232X","authenticated-orcid":false,"given":"Domitilla","family":"Baccon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2684-192X","authenticated-orcid":false,"given":"Jihao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3380-5326","authenticated-orcid":false,"given":"Suheil Albert","family":"Atallah-Yunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7463-0994","authenticated-orcid":false,"given":"Jacqueline F.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6536-1291","authenticated-orcid":false,"given":"Steven R.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-5531","authenticated-orcid":false,"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-8911","authenticated-orcid":false,"given":"Javier L.","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6752-5440","authenticated-orcid":false,"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Breen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4675-4903","authenticated-orcid":false,"given":"Ivana N.","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3939-6252","authenticated-orcid":false,"given":"Jithma P.","family":"Abeykoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin R.","family":"Klebig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-3163","authenticated-orcid":false,"given":"Allison C.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-1219","authenticated-orcid":false,"given":"Muhamad Alhaj","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-6238","authenticated-orcid":false,"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-6758","authenticated-orcid":false,"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-9132","authenticated-orcid":false,"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bneo.2026.100283_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17040696","article-title":"Updates on the biological heterogeneity of mantle cell lymphoma","volume":"17","author":"Ip","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100283_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hon.3149","article-title":"Mantle cell lymphoma-update on molecular biology, prognostication and treatment approaches","volume":"41","author":"Silkenstedt","year":"2023","journal-title":"Hematol Oncol"},{"issue":"26","key":"10.1016\/j.bneo.2026.100283_bib3","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bneo.2026.100283_bib4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s lymphoma classification project","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2026.100283_bib5","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.bneo.2026.100283_bib6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.hoc.2020.06.003","article-title":"Is limited-stage mantle cell lymphoma curable and how is it best managed? Hematology\/oncology clinics of North America","volume":"34","author":"Romancik","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"10.1016\/j.bneo.2026.100283_bib7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bneo.2026.100283_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/10428194.2012.711828","article-title":"Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital","volume":"54","author":"Bernard","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.bneo.2026.100283_bib9","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdg414","article-title":"Limited-stage mantle-cell lymphoma","volume":"14","author":"Leitch","year":"2003","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100283_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/17474086.2023.2174516","article-title":"Personalized approaches for treatment-na\u00efve mantle cell lymphoma","volume":"16","author":"Qualls","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100283_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70080","article-title":"Limited stage mantle cell lymphoma: a real-world study of primary treatment and prognosis in Sweden 2006-2018","volume":"9","author":"Albertsson-Lindblad","year":"2025","journal-title":"Hemasphere"},{"issue":"9","key":"10.1016\/j.bneo.2026.100283_bib12","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/annonc\/mdx334","article-title":"Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"28","author":"Dabaja","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2026.100283_bib13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijrobp.2015.07.2265","article-title":"Management trends and outcomes for stage I to II mantle cell lymphoma using the National Cancer Data Base: ascertaining the ideal treatment paradigm","volume":"93","author":"Gill","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl","key":"10.1016\/j.bneo.2026.100283_bib14","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.clml.2014.04.013","article-title":"Effect of radiotherapy on the survival of patients with stage I and stage II mantle cell lymphoma: analysis of the Surveillance, Epidemiology and End Results database","volume":"14","author":"Guru Murthy","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.bneo.2026.100283_bib15","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41409-025-02599-x","article-title":"How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives","volume":"60","author":"Dreger","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bneo.2026.100283_bib16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood.2023022352","article-title":"Frontline management of mantle cell lymphoma","volume":"145","author":"Ryan","year":"2025","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2026.100283_bib17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023022353","article-title":"Treatment of relapsed\/refractory MCL","volume":"145","author":"Silkenstedt","year":"2025","journal-title":"Blood"},{"issue":"9873","key":"10.1016\/j.bneo.2026.100283_bib18","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.bneo.2026.100283_bib19","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2026.100283_bib20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bneo.2026.100283_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3324\/haematol.2022.282469","article-title":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors","volume":"109","author":"Le Gouill","year":"2024","journal-title":"Haematologica"},{"issue":"10121","key":"10.1016\/j.bneo.2026.100283_bib22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.bneo.2026.100283_bib23","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100283_bib24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve cancer care in the United States","volume":"15","author":"Bilimoria","year":"2008","journal-title":"Ann Surg Oncol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:07:09Z","timestamp":1789646829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2950328026000944"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100283","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival benefit of chemoradiotherapy in limited-stage mantle cell lymphoma: a National Cancer Database analysis","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100283"}}